MAP have developed in-depth market access guides which will help you navigate through the complex market. All countries follow a set layout to simplify the process and make comparing different markets easier. Each country has an introductory market access overview and the relevant key stakeholders before delving into the pricing and reimbursement procedures. All MAP online members have access to MAP Europe which covers policies and regulations applicable to all EU countries.
Available to all members, MAP Europe covers key elements of market access that are applicable on a European level such as product licensing, international reference pricing and orphan designated products.
MAP UK spans across all four devolved nations, highlighting the similarities and differences between the market access process in England, Scotland, Wales and Northern Ireland.
Ireland has a thriving pharmaceutical industry with some of the largest companies setting up manufacturing plants in Ireland. The market access process in Ireland differs significantly to that in UK, with the use of wholesalers and basket pricing systems. As such we offer MAP Ireland complementary to all MAP UK members.
Since the start of the AMNOG-System in 2011, pricing and reimbursement in Germany has changed considerably. MAP Germany has been designed to support you when navigating the AMNOG-System to prepare the successful launch of innovative pharmaceuticals in Germany.
France has one of the largest pharmaceutical markets worldwide and it also enjoys one of the most successful healthcare systems in the world, based on a Bismarckian approach with Beveridge goals reflected. Learn more about these models on MAP.
The decentralised Spanish healthcare system makes it unique to most other European countries where each region is responsible for its healthcare system resulting in similar but slightly different healthcare systems across Spain.
MAP Italy provides an overview of the market access process in Italy, covering the key features such as the breakdown of the decentralised Italian healthcare system, the Motola reimbursement system and the different pricing classes for pharmaceuticals.
MAP Canada helps you navigate through the Canadian territories and provinces, helping you develop the an effective market access strategy. MAP Canada covers the different reimbursement processes and how they vary between the different regions in Canada.
MAP Japan guides you through the ever-changing market access environment in Japan. Learn how to benefit from the different priority schemes and pricing premiums available in Japan to achieve optimal pricing and reimbursement.
Learn how products enter the market in Brazil, where not all products undergo a HTA review by CONITEC. Understand who the key stakeholders and their role in the pricing and reimbursement processes
Turkey is a key emerging market for pharmaceutical companies with a well-organised pharmaceutical industry, following revisions to its pharmaceutical regulatory sector in 2013. Harmonising with EU rules has facilitated access to new medicines in Turkey, which has grown into an important market for the international pharmaceutical industry.